Delcath Systems Reports Second Quarter 2024 Results and Business Highlights

Rhea-AI Summary

Delcath Systems (Nasdaq: DCTH) reported Q2 2024 results, with total revenue of $7.8 million, including $6.6 million from HEPZATO KIT™ sales in the US and $1.2 million from CHEMOSAT sales in Europe. The company activated three new HEPZATO KIT treating centers in Q2, bringing the total to eight active centers. Delcath received New Technology Add-on Payment status for HEPZATO from CMS, published key results from the Phase 3 FOCUS study, and announced the acceptance of the FOCUS study efficacy analysis for presentation at the upcoming ESMO conference. The company ended the quarter with $19.9 million in cash and investments.

R&D expenses were $3.4 million, down from $3.6 million in Q2 2023, while SG&A expenses increased to $6.8 million from $4.8 million, primarily due to commercial launch activities. CEO Gerard Michel expressed optimism about HEPZATO KIT's adoption and its potential as a key therapeutic approach for metastatic uveal melanoma patients.

Positive

• Total revenue increased significantly to $7.8 million in Q2 2024, compared to $0.5 million in Q2 2023
• HEPZATO KIT sales in the US reached $6.6 million
• Activated three new HEPZATO KIT treating centers in Q2, bringing the total to eight active centers
• Received New Technology Add-on Payment status for HEPZATO from CMS
• Published key results from the Phase 3 FOCUS study in the Annals of Surgical Oncology
• Extended melphalan hydrochloride supply agreement with Synerx Pharma and Mylan Teoranta until December 31, 2028

Negative

• SG&A expenses increased to $6.8 million from $4.8 million in Q2 2023 due to commercial launch activities
• Cash and investments decreased to $19.9 million as of June 30, 2024

Insights

Financial Analyst

Delcath Systems' Q2 2024 results show significant revenue growth to $7.8 million, up from $0.5 million in the same period last year. This 1460% increase is primarily driven by $6.6 million in HEPZATO KIT sales in the U.S. and $1.2 million in CHEMOSAT sales in Europe. The company's cash position of $19.9 million provides a runway for continued commercialization efforts.

However, operating expenses have increased, with SG&A rising to $6.8 million from $4.8 million, reflecting investment in commercial launch activities. R&D expenses slightly decreased to $3.4 million. The company's focus on expanding its treating centers and securing NTAP status for HEPZATO suggests potential for further revenue growth, but investors should monitor the burn rate closely.

Oncology Expert

The adoption of HEPZATO KIT in treating metastatic uveal melanoma is progressing well, with eight active treating centers and more in the pipeline. The publication of the FOCUS study results in a peer-reviewed journal and upcoming presentation at ESMO add credibility to the treatment's efficacy. The CHOPIN trial's progress in evaluating CHEMOSAT with immunotherapy is promising for potential expanded indications.

The NTAP status for HEPZATO is significant, as it may improve hospital adoption rates by offsetting costs in inpatient settings. However, the primary outpatient use of HEPZATO KIT means this may have impact on overall sales. The positive physician feedback and CEO's optimism suggest HEPZATO KIT could become a standard treatment for metastatic uveal melanoma, potentially driving long-term growth for Delcath.

Company Reports $7.8 million in Quarterly Revenue

Conference Call Today at 4:30pm Eastern Time

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the second quarter ended June 30, 2024.

Recent Business Highlights

• Recognized second quarter 2024 revenues of $6.6 million from sales of HEPZATO KIT™ (melphalan/Hepatic Delivery System) and $1.2 million in CHEMOSAT sales;

• Activated three HEPZATO KIT treating centers in the US during the second quarter with an additional center in July for a total of eight active treating centers. Two additional centers have completed the necessary steps and have scheduled their first treatments in August. An additional four centers are ready to conduct their first commercial treatment and are currently in the process of scheduling patients for treatment;

• Received New Technology Add-on Payment status (NTAP) on August 1, 2024 for HEPZATO from the Centers for Medicare & Medicaid Services (CMS) which provides hospitals additional payments to cover the costs associated with the treatment for cases in the inpatient setting. While HEPZATO KIT is used primarily in the outpatient setting, there are instances where it is used in the inpatient setting;

• Published key results from the pivotal Phase 3 FOCUS study of HEPZATO KIT in patients with unresectable metastatic Uveal Melanoma in the journal Annals of Surgical Oncology;

• Announced the acceptance of the FOCUS study efficacy analysis as a poster presentation at the upcoming ESMO conference to be held September 2024;

• Reported that independent investigators at the Leiden University have enrolled 70 of the total 76 patients planned in the Phase 2 part of the CHOPIN trial which is evaluating the effect of sequencing Immunotherapy with CHEMOSAT liver directed therapy;

• Executed an amendment with Synerx Pharma, LLC and Mylan Teoranta for Delcath’s supply of melphalan hydrochloride which extends the term of the original agreement to December 31, 2028;

• Appointed Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024;

• Submitted the final principal payment due to Avenue Venture Opportunities Fund, L.P. (Avenue) on August 1, 2024 for the Loan and Security Agreement entered into in August 2021; and

• Ended the quarter with cash and investments of $19.9 million

“We are excited about the continued adoption of the HEPZATO KIT and the positive feedback from physicians,” said Gerard Michel, Delcath’s Chief Executive Officer. “We are optimistic that HEPZATO KIT will become a key part of the therapeutic approach for metastatic uveal melanoma patients.”

Second Quarter 2024 Results

Total revenue for the quarter ended June 30, 2024 was $7.8 million compared to $0.5 million for the same period in the prior year. Revenues include sales of $6.6 million of HEPZATO in the U.S. and $1.2 million of CHEMOSAT in Europe.

Research and development expenses for the quarter ended June 30, 2024, were $3.4 million compared to $3.6 million for the same period in the prior year. The change in research and development expenses is primarily due to lower costs associated with NDA submission incurred in previous periods offset by an increase in medical affairs and regulatory costs associated with an approved product.

Selling, general and administrative expenses for the quarter ended June 30, 2024, were $6.8 million compared to $4.8 million for the same period in the prior year. The increase primarily relates to commercial launch activities including marketing-related expenses and additional personnel in the commercial team.

Cash, cash equivalents and investment totaled $19.9 million as of June 30, 2024.

Conference Call Information

To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.

Event Date:		Monday, August 5, 2024
Time:		4:30 PM Eastern Time
Participant Numbers
Toll Free:		1-877-407-3982
International:		1-201-493-6780
Webcast:		https://viavid.webcasts.com/starthere.jsp?ei=1679582&tp_key=87da4fb106

A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company’s website: https://delcath.com/investors/events-presentations/

About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT^® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating the hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

Safe Harbor / Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company's commercialization plans and its ability to successfully commercialize the HEPZATO KIT; the Company's successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company's successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company's ability to obtain reimbursement for the HEPZATO KIT; and the Company's ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company's filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

DELCATH SYSTEMS, INC. Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share data)
		June 30, 2024				December 31, 2023
Assets
Current assets
Cash and cash equivalents		$	14,782			$	12,646
Restricted cash			—				50
Short-term investments			5,124				19,808
Accounts receivable, net			3,726				241
Inventory			6,316				3,322
Prepaid expenses and other current assets			1,451				1,091
Total current assets			31,399				37,158
Property, plant and equipment, net			1,422				1,352
Right-of-use assets			1,092				103
Total assets		$	33,913			$	38,613
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable		$	3,279			$	1,012
Accrued expenses			4,418				5,249
Lease liabilities, current			103				37
Loan payable			—				5,239
Convertible notes payable			4,491				4,911
Total current liabilities			12,291				16,448
Warrant liability			15,809				5,548
Lease Liabilities, non-current			989				—
Other liabilities, non-current			632				840
Total liabilities			29,721				22,836
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized; 12,342 and 24,819 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively			—				—
Common stock, $0.01 par value; 80,000,000 shares authorized; 27,931,393 shares and 22,761,554 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively			279				228
Additional paid-in capital			533,919				520,576
Accumulated deficit			(530,014	)			(505,162	)
Accumulated other comprehensive loss			8				135
Total stockholders’ equity			4,192				15,777
Total liabilities and stockholders’ equity		$	33,913			$	38,613

DELCATH SYSTEMS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data)
		Three months ended June 30,								Six months ended June 30,
		2024				2023				2024				2023
Product revenue		$	7,766			$	495			$	10,905			$	1,092
Cost of goods sold			(1,519	)			(150	)			(2,422	)			(331	)
Gross profit			6,247				345				8,483				761
Operating expenses:
Research and development expenses			3,394				3,555				7,094				8,131
Selling, general and administrative expenses			6,765				4,787				15,579				8,952
Total operating expenses			10,159				8,342				22,673				17,083
Operating loss			(3,912	)			(7,997	)			(14,190	)			(16,322	)
Change in fair value of warrant liability			(9,755	)			1,160				(10,367	)			1,160
Interest expense, net			(84	)			(371	)			(283	)			(1,059	)
Other (expense) income			10				6				(12	)			19
Net loss			(13,741	)			(7,202	)			(24,852	)			(16,202	)
Other comprehensive (loss) income:
Unrealized gain on investments			(141	)			—				(133	)			—
Foreign currency translation adjustments			(8	)			—				6				19
Total comprehensive loss		$	(13,890	)		$	(7,202	)		$	(24,979	)		$	(16,183	)
Common share data:
Basic and diluted loss per common share		$	(0.48	)		$	(0.58	)		$	(0.93	)		$	(1.35	)
Weighted average number of basic and diluted shares outstanding			28,364,731				12,463,665				26,625,955				12,035,738

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240805008997/en/

Investor Relations:

ICR Westwicke

investorrelations@delcath.com

Source: Delcath Systems, Inc.

FAQ

What was Delcath Systems' (DCTH) total revenue for Q2 2024?

Delcath Systems reported total revenue of $7.8 million for Q2 2024, including $6.6 million from HEPZATO KIT sales in the US and $1.2 million from CHEMOSAT sales in Europe.

How many HEPZATO KIT treating centers did Delcath (DCTH) activate in Q2 2024?

Delcath activated three new HEPZATO KIT treating centers in Q2 2024, bringing the total number of active treating centers to eight.

What was the status of Delcath's (DCTH) cash and investments as of June 30, 2024?

Delcath Systems ended Q2 2024 with cash and investments totaling $19.9 million as of June 30, 2024.

Did Delcath (DCTH) receive any regulatory updates for HEPZATO KIT in Q2 2024?

Yes, Delcath received New Technology Add-on Payment (NTAP) status for HEPZATO from the Centers for Medicare & Medicaid Services (CMS) on August 1, 2024.

What clinical study results did Delcath (DCTH) publish in Q2 2024?

Delcath published key results from the pivotal Phase 3 FOCUS study of HEPZATO KIT in patients with unresectable metastatic Uveal Melanoma in the journal Annals of Surgical Oncology.